Nasal Spray Container Determination Should Precede Clinical Testing – FDA
This article was originally published in The Tan Sheet
Executive Summary
Container closure systems for nasal spray and inhalant drugs should be tested and found appropriate for use with a particular drug compound prior to conducting clinical and stability tests, an FDA guidance states
You may also be interested in...
Metered dose inhalers
Dose-counting mechanisms for metered dose oral inhalers recommended by FDA in Dec. 11 Federal Register. Guidance, noting patients may either use products for too long or throw away inhalers that still have acceptable doses left in them, states "dose-counters should provide, either though a direct numeric count or color coding, a clear indication of when an MDI is approaching the end of its recommended number of actuations, as well as when it has reached or exceeded that number"...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands